BIOMARKER:

FGFR3 mutation

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

FGFR3 mutation	Urothelial Cancer	FGFR3 mutation	Urothelial Cancer	erdafitinib Sensitive: A1 - Approval erdafitinib Sensitive : A1	erdafitinib Sensitive: A1 - Approval erdafitinib Sensitive : A1
FGFR3 mutation	Urothelial Cancer	FGFR3 mutation	Urothelial Cancer	BAY 1163877 Sensitive: B - Late Trials BAY 1163877 Sensitive : B	BAY 1163877 Sensitive: B - Late Trials BAY 1163877 Sensitive : B
FGFR3 mutation	Cholangiocarcinoma	FGFR3 mutation	Cholangiocarcinoma	erdafitinib Sensitive: C1 - Off-label erdafitinib Sensitive : C1	erdafitinib Sensitive: C1 - Off-label erdafitinib Sensitive : C1
FGFR3 mutation	Gastric Cancer	FGFR3 mutation	Gastric Cancer	erdafitinib Sensitive: C1 - Off-label erdafitinib Sensitive : C1	erdafitinib Sensitive: C1 - Off-label erdafitinib Sensitive : C1
FGFR3 mutation	Urothelial Cancer	FGFR3 mutation	Urothelial Cancer	infigratinib Sensitive: C2 – Inclusion Criteria infigratinib Sensitive : C2	infigratinib Sensitive: C2 – Inclusion Criteria infigratinib Sensitive : C2
FGFR3 mutation	Urothelial Cancer	FGFR3 mutation	Urothelial Cancer	pemigatinib Sensitive: C2 – Inclusion Criteria pemigatinib Sensitive : C2	pemigatinib Sensitive: C2 – Inclusion Criteria pemigatinib Sensitive : C2
FGFR3 mutation	Bladder Cancer	FGFR3 mutation	Bladder Cancer	infigratinib Sensitive: C2 – Inclusion Criteria infigratinib Sensitive : C2	infigratinib Sensitive: C2 – Inclusion Criteria infigratinib Sensitive : C2
FGFR3 mutation	Breast Cancer	FGFR3 mutation	Breast Cancer	infigratinib Sensitive: C2 – Inclusion Criteria infigratinib Sensitive : C2	infigratinib Sensitive: C2 – Inclusion Criteria infigratinib Sensitive : C2
FGFR3 mutation	Urothelial Cancer	FGFR3 mutation	Urothelial Cancer	TAS 120 Sensitive: C2 – Inclusion Criteria TAS 120 Sensitive : C2	TAS 120 Sensitive: C2 – Inclusion Criteria TAS 120 Sensitive : C2
FGFR3 mutation	Non Small Cell Lung Cancer	FGFR3 mutation	Non Small Cell Lung Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
FGFR3 mutation	Non Small Cell Lung Cancer	FGFR3 mutation	Non Small Cell Lung Cancer	nintedanib Sensitive: C3 – Early Trials nintedanib Sensitive : C3	nintedanib Sensitive: C3 – Early Trials nintedanib Sensitive : C3
FGFR3 mutation	Urothelial Cancer	FGFR3 mutation	Urothelial Cancer	B-701 Sensitive: C3 – Early Trials B-701 Sensitive : C3	B-701 Sensitive: C3 – Early Trials B-701 Sensitive : C3
FGFR3 mutation	Urothelial Cancer	FGFR3 mutation	Urothelial Cancer	enfortumab vedotin Resistant: C3 – Early Trials enfortumab vedotin Resistant : C3	enfortumab vedotin Resistant: C3 – Early Trials enfortumab vedotin Resistant : C3
FGFR3 mutation	Solid Tumor	FGFR3 mutation	Solid Tumor	CPL304110 Sensitive: D – Preclinical CPL304110 Sensitive : D	CPL304110 Sensitive: D – Preclinical CPL304110 Sensitive : D
FGFR3 mutation	Endometrial Cancer	FGFR3 mutation	Endometrial Cancer	infigratinib Sensitive: D – Preclinical infigratinib Sensitive : D	infigratinib Sensitive: D – Preclinical infigratinib Sensitive : D
FGFR3 mutation	Urothelial Cancer	FGFR3 mutation	Urothelial Cancer	dasatinib + infigratinib Sensitive: D – Preclinical dasatinib + infigratinib Sensitive : D	dasatinib + infigratinib Sensitive: D – Preclinical dasatinib + infigratinib Sensitive : D